Table 3.

Patient characteristics of stage I AC patients according to MDM2 genotypes

		MDM2 genotypes						T/T vs. T/G vs. G/G	T/T vs. T/G + G/G
	Total	T/T		T/G		G/G		P a	P a
All cases	246	58	23.6	115	46.7	73	29.7	–	–
Sex
Women	134	27	20.3	65	48.9	41	20.8	0.42	0.23
Men	113	31	27.4	50	44.2	32	28.3
Age in years
<70	135	33	24.4	63	46.7	39	28.9	0.92	0.76
≥70	111	25	23.6	52	46.8	34	30.6
Smoking status
Never smoker	140	24	17.1	73	52.1	43	30.7	0.02	0.01
Smoker	106	34	32.1	42	39.6	30	28.3
p53 Arg72Pro
Arg/Arg	90	20	22.2	42	46.7	28	31.1	0.90	0.93
Arg/Pro	115	28	24.3	56	48.7	31	27.0
Pro/Pro	41	10	24.4	17	41.5	14	34.1
Performance statusb
0	208	49	23.6	101	48.6	58	27.9	0.30	1.00
1–2	21	5	23.8	7	33.3	9	42.9
Surgical procedure
Lobectomy	201	49	24.4	91	45.3	61	30.3	0.61	0.70
Segmentectomy	45	9	20.0	24	53.3	12	26.7
Differentiation
Well	137	30	21.9	69	50.4	38	27.7	0.44	0.55
Moderate or poorly	109	28	25.7	46	42.2	35	32.1
T factor
T1	158	35	21.5	71	44.9	53	33.5	0.19	0.35
T2	88	24	27.3	44	50.0	20	22.7
Pleural invasion
Absent	202	42	20.8	96	47.5	64	31.7	0.07	0.03
Present	44	16	36.4	19	43.2	9	20.5
Lymphovascular invasion
Absent	177	34	19.2	92	52.0	51	28.8	0.01	0.01
Present	69	24	34.8	23	33.3	22	31.9
p53 status
Wild type	207	48	23.2	98	47.3	61	29.5	0.90	0.83
Mutant	39	10	25.6	17	43.6	12	30.8
EGFR statusb
Wild type	133	30	22.6	62	46.6	41	30.8	0.92	0.76
Mutant	111	27	24.3	52	46.8	32	28.8
KRAS status
Wild type	214	54	25.2	99	46.3	61	28.5	0.25	0.13
Mutant	32	4	12.5	16	50.0	12	37.5
Adjuvant chemotherapy
Received	47	14	29.8	27	57.4	6	12.8	0.02	0.26
Not received	199	44	22.1	88	44.2	67	33.7
Chemotherapy
Received	16	3	18.8	9	56.2	4	5.5	0.80	0.55
Not received	11	4	36.4	4	36.4	3	27.31

NA, not available; AC, adenocarcinoma.

^a P values were calculated by chi‐square test. P < 0.05 are shown in bold.

^bPerformance status at surgery and EGFR mutation status remains unknown in some cases.